Nouryon Overview
Nouryon is a carve-out specialty chemicals platform built from the former specialty chemicals arm of AkzoNobel and owned since 2018 by Carlyle and GIC. It manufactures performance ingredients and process chemicals — surfactants, chelates, cellulose ethers, organic peroxides, metal alkyls, colloidal silica, expandable microspheres, chromatography media and pulp-bleaching chemicals — that customers use to make consumer and industrial products. Revenue is roughly $5.1bn, generated through roughly 63 plants and sold in more than 80 countries. Its competitive identity rests on a portfolio of global or regional leadership positions in niche, technically demanding chemistries (Expancel®, Kromasil®, Levasil®, Bermocoll®, Dissolvine®), long-term integrated supply contracts with pulp mills, and a disciplined, Axalta-style private-equity operating model under CEO Charlie Shaver. The investment debate centres on high adjusted EBITDA margins (~22.5%) and solid free cash flow set against heavy leverage (~5.0x), recurring IPO deferrals and cyclic exposure to polymer and pulp markets.
What the company does
Nouryon produces specialty and performance chemicals that enter customer formulations or manufacturing processes as functional ingredients, catalysts, initiators or process aids. The company itself characterises its output as "essential solutions" that customers use to manufacture everyday products in attractive end-markets, and it describes the business in its fact sheet as a global specialty chemicals leader operating in more than 80 countries with a portfolio of industry-leading brands (Nouryon company fact sheet). In its 2025 sustainability report the company frames growth as coming from innovating safer, more efficient and more sustainable chemistry for customers (Nouryon 2025 Sustainability Report release, 7 May 2026).
Company's own description (paraphrased from latest public materials)
Nouryon presents itself as a global specialty chemicals leader whose products are used in personal care, cleaning goods, paints and coatings, agriculture and food, pharmaceuticals, building products, polymers, pulp and paper, oil and gas, and mining. Since the Q3 2024 reorganisation it organises around three segments — Consumer & Life Sciences, Performance Materials and Resource Solutions — and six business units (FY2024 results release, 7 Mar 2025).
Independent characterisation
Nouryon is best understood as a portfolio of ~30–40 mid-sized niche chemistry franchises sharing a common manufacturing, procurement and commercial backbone. Roughly three economic archetypes coexist:
-
Formulated consumer ingredients (surfactants, chelates, cellulose ethers, polymers for home & personal care, agro adjuvants, micronutrients): moderate cyclicality, sticky qualification, pricing tied to raw materials (ethylene oxide, fatty amines, cellulose).
-
Polymer process chemistry (organic peroxides, metal alkyls, PVC reactor additives): technically demanding, hazardous-materials handling acts as a barrier to entry; volumes track polyolefin and PVC operating rates, notably in China.
-
Resource / pulp chemistry (sodium chlorate, chlorine dioxide, hydrogen peroxide, mining and oilfield chemicals): energy-intensive and contract-based, with 10–15-year integrated "chemical island" supply agreements for pulp mills, especially in South America.
Business and revenue model
| Revenue model element | Estimated share | Comment |
|---|---|---|
| Product sales (B2B chemicals, spot + contract) | ~95%+ | Core model; priced per tonne, often with raw-material pass-through clauses |
| Long-term integrated supply (pulp-mill "Integrated Manufacturing Model") | n/d (embedded in Resource Solutions) | 10–15-year agreements, e.g., Suzano (15-year, 2022), Metsä Fibre (2021), Arauco MAPA (2023), Bracell (2021) |
| Technology licensing | Small, n/d | e.g., CiD PVC technology license in China (Jul 2021); SulNOx fuel additive licensing (trade press) |
| Services / subscription | Negligible | Digital tools (My Nouryon portal; BeautyCreations™ AI formulation tool) support sales but are not separately monetised (n/d) |
Value chain position
Nouryon sits mid-stream: it buys base chemicals and energy (ethylene, ethylene oxide, fatty raw materials, salt/chlor-alkali derivatives — some from sister company Nobian — cellulose, aluminium, electricity), converts them into functional intermediates, and sells to formulators and manufacturers (consumer goods companies, paint makers, polymer producers, pulp mills, agrochemical formulators, pharma manufacturers). Distribution partners include IMCD and Brenntag Specialties for selected regions and lines.
Customer types and end-markets
| End-market cluster | Representative products | Representative named customers/partners (public) |
|---|---|---|
| Home & personal care | Surfactants, chelates (Dissolvine®), polymers, CMC, Structure® starches, Armocare® | Henkel Consumer Brands (2025 sustainability award) |
| Agriculture & food | Adjuvants (Adsee®), micronutrients (HBED, EDDHA), ADOB fertilizers, food-grade ingredients | — |
| Pharma & life sciences | Kromasil® chromatography media (peptide/GLP-1 purification) | — |
| Paints, coatings & inks | Bermocoll® cellulose ethers, Expancel® microspheres, rheology modifiers | — |
| Polymers | Organic peroxides, metal alkyls (TEAL, MMAO), PVC additives, recycled-PP restoration | Petro Rabigh (2024 supplier award) |
| Pulp, paper & packaging | Sodium chlorate, chlorine dioxide plants, hydrogen peroxide, Expancel® for paperboard | Suzano, Arauco, Metsä Fibre, Bracell |
| Oil, gas & mining | Demulsifiers, collectors, oilfield surfactants | — |
| Building & infrastructure | Asphalt additives, cellulose ethers, colloidal silica | Brenntag (US asphalt distribution) |
| Electronics, catalysts, batteries | Levasil® colloidal silica, high-purity metalorganics | — |
Strategy
Stated strategy (themes, paraphrased)
From company materials (fact sheet, sustainability report, results releases):
-
Grow by innovating sustainable solutions for customers — "eco-premium solutions" reached 36% of 2025 revenue, and 76% of the R&D pipeline targets sustainability benefits (bio-based feedstocks, biodegradability, lower footprint).
-
Focus on attractive, high-growth end-markets — explicit prioritisation of investments in innovation, capex and acquisitions by segment since the 2024 reorganisation (Larry Ryan, FY2024 release).
-
Operational excellence and responsible operations — process safety, emissions, waste and water reduction; framed in the "Sustainable Growth Framework" (innovate & grow / operate responsibly / empower & engage).
-
Bolt-on M&A — repeatedly stated by Shaver (Friend, Huber CMC, ADOB, Singapore plant).
-
Localisation in emerging markets — China, India, Brazil, Middle East.
-
Balance-sheet deleveraging — leverage reduced from 5.7x to 5.0x in 2024; repricings and maturity extensions.
Strategic initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Type | Detail |
|---|---|---|---|
| Kromasil® capacity doubling (Sweden) | Feb 2025 | Capacity | Targeted at peptide-based diabetes and obesity (GLP-1) drug purification |
| Saudi Arabia office (Al Dhahran) | Feb 2025 | Market expansion | Middle East presence |
| Repricings; securitization and revolver upsized/extended | 2024–early 2025 | Financing | Liquidity profile improved |
| BeautyCreations™ AI formulation tool | Apr 2025 | Digital | AI-driven personal care formulation discovery |
| Texas oilfield innovation centre | Jun 2025 | R&D | Oilfield solutions |
| Singapore onsite solar | Jun 2025 | Decarbonisation | Onsite PV |
| South America sodium chlorate +20% | Aug 2025 | Capacity | Supports Arauco pulp mill |
| China metal alkyls doubling; MMAO; Tianjin centre | Oct 2025 | Capacity/R&D | Polymer Specialties leadership |
| Shanghai innovation centre | Nov 2025 | R&D | Eight labs |
| Brazil HPC innovation centre | Dec 2025 | R&D/commercial | South America growth |
| IMCD textile & leather partnership (EMEA) | Dec 2025 | Channel | Distribution |
| Biobased CMC launch | Feb 2026 | Product | Laundry |
| Ketone peroxide price increase (up to 30%) | Apr 2026 | Pricing | Margin recovery/input costs |
| China colloidal silica expansion | Apr 2026 | Capacity | Catalysts, advanced coatings |
| Recycled PP restoration solution | May 2026 | Product | Circularity |
| Mid-2026 refinancing (TLBs + €450M notes) | Jun–Jul 2026 | Financing | Extends 2028 maturities to ~2031 |
| CTO and CHRO appointments | 2,026 | Organisation | Innovation and talent leadership refresh |
| Morris, Illinois solar | Oct 2026 | Decarbonisation | US renewable electricity |
Medium-term targets / guidance
Nouryon does not publish financial guidance or medium-term financial targets (private). Sustainability targets are referenced on its website (2019 baseline for Scope 1+2 reductions); progress was 22% absolute Scope 1+2 reduction vs 2019 by 2025. The specific 2030 target percentages were not captured in sources reviewed (n/d here; see company "Sustainability targets" page).
Products & Services
Launch years are those found in company releases; "Established" = longstanding heritage franchise with no single launch date disclosed. Pricing is not publicly disclosed for any line except where a price-increase announcement is noted.
Consumer & Life Sciences
| Product line / brand | Description & capabilities | Target customer | Launch / latest version | Pricing notes |
|---|---|---|---|---|
| Berol® surfactants (incl. Berol® Nexxt, Berol® Nexus) | Non-ionic surfactants and hydrotropes for cleaning; Nexus is a multifunctional hydrotrope | Household, industrial & institutional cleaning formulators | Nexxt 2023; Nexus Jan 2024 | — |
| Dissolvine® chelates (incl. GL Premium; biodegradable GLDA) | Chelating agents for detergents, auto-dish, water treatment; bio-based GLDA made at Herkenbosch (ISCC PLUS) | Detergent makers, water treatment | GL Premium 2023; Herkenbosch expansion Feb 2022 | — |
| Biobased CMC for laundry | Industry-first 100% biobased, biodegradable carboxymethylcellulose for detergents | Laundry detergent brands | Feb 2026 | — |
| Cationic surfactants & fatty amines (Armeen®, Arquad®, Ethomeen®, Triameen®) | Antimicrobial actives (Triameen® Y12D), conditioning agents, emulsifiers | Disinfection, personal care, industrial | Triameen® Y12D Jan 2023 | — |
| Armocare® Aqua 12 | ISCC PLUS-certified biodegradable conditioning surfactant for hair care | Hair-care brands | Apr 2025 | — |
| Structure® starches (Structure® M3, Structure® Silk) | Rheology modifiers/texturizers and co-surfactants for personal care | Personal care formulators | M3 Apr 2024; Silk Sep 2024 | — |
| SolAmaze® Natural | Natural sun-care film former (Allē Award 2022) | Sun-care brands | Established; award Oct 2022 | — |
| Halal-certified ingredients (China) | Halal-certified personal care & cleaning ingredients | China/APAC consumer markets | Mar 2026 | — |
| BeautyCreations™ | AI-driven personal care formulation discovery tool (digital service) | Personal care formulators | Apr 2025 | Free-to-use |
| Demeon® dimethyl ether (incl. Demeon® ReNu100) | Aerosol propellant; ReNu100 is biobased; green DME ISCC PLUS-certified | Aerosol fillers | ReNu100 Apr 2025 | Price increase announced Apr 2022 |
| Adsee® adjuvants (incl. Adsee® Flex 960) | Tank-mix adjuvants for crop protection efficacy | Agrochemical formulators, distributors | Flex 960 Apr 2025 | — |
| Agrilan® dispersants (e.g., Agrilan® 1015) | Biodegradable dispersant for agro formulations (ACC Sustainability award 2022) | Agrochemical formulators | Established | — |
| Micronutrients — Dissolvine® X, Bolikel® XP (Fe-HBED), Dissolvine® Q (Fe-EDDHA), Dissolvine® Combi | Chelated iron and other micronutrients; HBED is a patented, exclusively-produced iron chelate for high-pH soils | Fertilizer makers, growers | HBED promoted 2025–26 | — |
| ADOB fertilizers (Poland) | Chelated micronutrient and foliar fertilizers | Crop nutrition channel | Acquired Jan 2023 | — |
| Kromasil® chromatography media | High-purity spherical silica for HPLC/prep purification, incl. peptide (GLP-1) purification; capacity doubling in Sweden announced Feb 2025 | Pharma & biotech manufacturers | New peptide grade Jun 2023 | — |
| Moisturizing agents, food & animal-nutrition ingredients | Humectants and food/feed additives | Food, feed, personal care | Established | — |
| Biocides | Biocidal actives for cleaning and preservation | Cleaning, industrial | Established | — |
Performance Materials
| Product line / brand | Description & capabilities | Target customer | Launch / latest version | Pricing notes |
|---|---|---|---|---|
| Organic peroxides (Trigonox®; Perkadox®; Butanox®; Laurox®) | Initiators and crosslinkers for polymerisation (LDPE, PVC, acrylics), curing of thermosets | Polymer producers, composites | China expansions 2023–2024; Tianjin innovation centre 2026 | Ketone peroxides: up to 30% global price increase effective 1 Apr 2026 |
| Metal alkyls (TEAL and others) | Co-catalysts for polyethylene/polypropylene; Jiaxing TEAL capacity doubled 2025 | Polyolefin producers | Expansion completed Oct 2025 | — |
| MMAO (modified methylaluminoxane) | Catalyst component for polyolefin elastomers (e.g., solar encapsulants) | Polyolefin elastomer producers | China production from 2027 | — |
| High-purity metalorganics | Precursors for compound semiconductors/LEDs | Electronics | Established | — |
| PVC reactor additives (incl. CiD technology) | Additives/technology for PVC polymerisation; first CiD licence in China 2021 | PVC producers | Licence Jul 2021 | Licensing (n/d) |
| Polymer additives & recycling solutions | Includes first commercially available solution to restore recycled polypropylene performance | Packaging, automotive, consumer-goods compounders | May 2026 | — |
| Expancel® expandable microspheres (incl. BIO, XS200, HP92, WB, paperboard grade) | Thermoplastic microspheres for lightweighting, foaming, texture; BIO is partially biobased | Coatings, sealants, footwear, paperboard, automotive | BIO Dec 2024; XS200 Mar 2025; paperboard grade Apr 2026 | — |
| Bermocoll® cellulose ethers (incl. EHM MAX, FLOW) | Rheology modifiers/thickeners for waterborne paints | Architectural paint producers | FLOW Apr 2022; EHM MAX Mar 2025 | — |
| Low-odor architectural paint technology | Technology for higher-performing low-odour paints | Paint formulators | Apr 2026 | — |
| Thioplast® polysulfides | Polysulfide polymers for sealants (insulating glass, aerospace) | Sealant makers | Established | — |
| Synthetic, hybrid and biopolymers | Dispersants, film formers | Coatings, cleaning | Established | — |
Resource Solutions
| Product line / brand | Description & capabilities | Target customer | Launch / latest version | Pricing notes |
|---|---|---|---|---|
| Sodium chlorate (Eka® heritage) | Feedstock for chlorine dioxide pulp bleaching; South America capacity +20% (Aug 2025) | Kraft pulp mills | Brazil (MS) start Sep 2024 | Long-term contracts |
| Chlorine dioxide plants / Integrated Manufacturing Model ("chemical island") | On-site bleaching chemical plants operated for pulp mills | Pulp producers (Suzano, Arauco, Bracell, Metsä Fibre) | Arauco MAPA commissioned Mar 2023 | Multi-year contracts |
| Hydrogen peroxide (incl. low-carbon Nordic grade) | Bleaching and oxidising agent | Pulp, chemicals | Low-carbon H2O2 Mar 2025 | — |
| Potassium chlorate | Oxidiser for matches/pyrotechnics | Matches, pyrotechnics | Established | — |
| Levasil® colloidal silica | Binders for catalysts, coatings, electronics polishing, paper | Catalyst producers, coatings, electronics | US +50% Jan 2024; China expansion Apr 2026 | — |
| Oilfield chemicals (demulsifiers, surfactants) | Production and stimulation chemistry | Oil & gas operators/service companies | Texas innovation centre Jun 2025 | — |
| Mining collectors & process aids | Flotation chemistry | Mining | Established | — |
| Fuels & lubricants additives | Specialty surfactants and polymers; IMCD partnership (2023) | Lubricant/fuel formulators | Established | — |
| LumaTreat® tagged polymers | Smart-tagged scale inhibitors for water treatment (US patent 2022) | Water-treatment service firms | Mar 2021 | Distributed via Brenntag (US/Canada) |
| Asphalt additives | Emulsifiers/adhesion promoters | Road construction | Established | Brenntag distribution (US) |
| Ethylene amines & ethanolamines, MCA, sulfur products, alkali pellets | Intermediates (some ISCC PLUS "green" grades) | Chemical industry | Green MCA Dec 2023 | — |
| Textile & leather solutions | Specialty auxiliaries | Textile/leather processors | IMCD EMEA partnership Dec 2025 | — |
Segment allocation of some intermediate lines (MCA, ethylene amines, DME) between segments is n/d; placement above is analyst judgement.
Financial Narrative
Income statement
0 = not publicly disclosed in sources reviewed. FY2025 revenue = company-stated "~$5.1B" (approximate). FY2022 adjusted EBITDA derived (FY2021 $1,081M × 1.15 ≈ $1,243M; FY2023 $1,055M ÷ 0.84 ≈ $1,256M; midpoint shown). FY2021 margin 22.0% reported (FY2020: 23.4%). Gross profit, operating income, pre-tax income, EPS and dividends per share: not publicly disclosed (Nouryon is private; EPS/DPS not applicable). Sources: FY2021–FY2024 results releases; Sustainability Fact Sheet 2025.
Commentary. The five-year arc has three phases. (i) 2021–2022 inflationary price surge: revenue rose 17% in each year, with 2022 growth (24% ex-FX) almost entirely price-driven as Nouryon passed through energy and raw-material inflation; adjusted EBITDA reached a peak of roughly $1.25bn. (ii) 2023 destocking trough: revenue fell 10% (−8% ex-FX), driven by volume declines in agriculture, coatings and consumer channels, and adjusted EBITDA fell 16% to $1.055bn. (iii) 2024 volume recovery with margin expansion: volume rose 6.5% across all regions and business units while pricing fell in line with lower input costs; revenue was flat ex-FX, yet adjusted EBITDA grew 9.5% and margin expanded 220bp to 22.5% — evidence that 2022 pricing gains were partially "sticky" relative to raw-material deflation. FY2025 revenue (~$5.1bn) suggests a broadly flat top line; FY2025 EBITDA was not found in public sources.
The FY2024 IFRS net loss of $339M highlights the leveraged-buyout structure: $545M of finance costs and a $221M net FX loss (largely on euro-denominated debt and intercompany balances) more than absorbed operating profit.
Cash flow
Capex derived as OCF − FCF (company defines FCF = OCF − capex). FY2023 "adjusted free cash flow" separately reported as $655M (−26% YoY), implying FY2022 adjusted FCF of ~$885M (derived). Dividends/buybacks: none disclosed (private; any shareholder distributions n/d). Sources: FY2023 and FY2024 results releases.
Commentary. OCF improved 47% in 2023 on working-capital release during destocking, then held near $1bn in 2024. Capex normalised in 2024 after "three years of elevated growth investments" (CFO Sean Lannon, FY2024 release), lifting FCF 21% to $728M. Growth projects completed in 2021–2024 include Brazil sodium chlorate, US Expancel®, China organic peroxides, Singapore alkoxylation, US Levasil® and Dutch chelates.
Balance sheet and leverage
Net debt derived = leverage × adjusted EBITDA. The 2026 refinancing repaid US$3,102M TLB due 2028, US$733M incremental TLB due 2028 and €1,692M (~US$1,941M) TLB due 2028 (sum ≈ US$5,776M equivalent), using new US$3.35bn and €1.692bn TLBs plus €450M senior secured notes. Total assets, cash, goodwill & intangibles, equity and working capital: not publicly disclosed in sources reviewed. Sources: FY2024 results release; CreditFlow Research (2026).
Ratios
Interpretation. Interest coverage near 2x on adjusted EBITDA and leverage of ~5x place Nouryon squarely in single-B territory, consistent with B2/B+ ratings. The mid-2026 refinancing primarily extends maturities from 2028 to ~2031 and diversifies the stack with fixed-rate euro notes (6.125%).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Business units | What it contains | Senior leader |
|---|---|---|---|
Consumer & Life Sciences (C&LS) | Home & Personal Care (HPC); Life Sciences (former Agriculture & Food plus pharma) | Surfactants, chelates, polymers and ingredients for cleaning, personal care, crop nutrition/protection, food, animal nutrition, pharma (Kromasil®) | Suzanne M. Carroll, EVP |
Performance Materials (PM) | Polymer Specialties; Paints & Coatings | Organic peroxides, metal alkyls, PVC additives, Expancel®, Bermocoll® cellulose ethers, rheology modifiers | Alain Rynwalt, SVP |
Resource Solutions (RS) | Renewable Fibers; Industrials (renamed from Natural Resources) | Pulp bleaching chemistry (sodium chlorate, ClO2, H2O2), mining and oilfield chemicals, fuels and lubricants additives | Joppe Smit, SVP |
Segment revenue (USD Mn)
| Segment revenue (USD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Consumer & Life Sciences | 2,277 | 2,300 | 0 |
Performance Materials | 1,790 | 1,740 | 0 |
Resource Solutions | 1,130 | 1,095 | 0 |
Total company | 5,190 | 5,130 | 5,100 |
Segment adjusted EBITDA (USD Mn)
| Segment adjusted EBITDA (USD Mn) | FY2023 | FY2024 |
|---|---|---|
Consumer & Life Sciences | 453 | 517 |
Performance Materials | 348 | 372 |
Resource Solutions | 251 | 266 |
Segment adjusted EBITDA margin (%)
| Segment adjusted EBITDA margin (%) | FY2023 | FY2024 |
|---|---|---|
Consumer & Life Sciences | 20.1 | 22.6 |
Performance Materials | 19.4 | 21.3 |
Resource Solutions | 22.3 | 24.3 |
Segment Overview — Consumer & Life Sciences
| Segment | Revenue YoY (%) | Volume YoY (%) | Adj. EBITDA YoY (%) | % of group revenue | % of segment EBITDA |
|---|---|---|---|---|---|
Consumer & Life Sciences | 1 | 9 | 14 | 45 | 45 |
Performance Materials | -3 | 5 | 7 | 34 | 32 |
Resource Solutions | -3 | 4 | 6 | 21 | 23 |
Legacy segment revenue (USD Mn)
| Legacy segment revenue (USD Mn) | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
Performance Formulations | 3,400 | 4,150 | 3,600 |
Technology Solutions | 1,500 | 1,630 | 1,600 |
Legacy segment adjusted EBITDA (USD Mn)
| Legacy segment adjusted EBITDA (USD Mn) | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
Performance Formulations | 745 | 922 | 678 |
Technology Solutions | 335 | 335 | 362 |
Legacy segment adjusted EBITDA margin (%)
| Legacy segment adjusted EBITDA margin (%) | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
Performance Formulations | 21.9 | 22.2 | 19.0 |
Technology Solutions | 22.3 | 20.6 | 22.6 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (USD Mn) | 4,900 | 5,800 | 5,190 | 5,130 | 5,100 |
Revenue growth YoY (%) | 17 | 17 | -10 | -1.1 | -0.6 |
Adjusted EBITDA (USD Mn) | 1,081 | 1,250 | 1,055 | 1,155 | 0 |
Adjusted EBITDA margin (%) | 22.0 | 21.6 | 20.3 | 22.5 | 0 |
Profit/(loss) for the year (USD Mn) | 0 | 0 | 0 | -339 | 0 |
Finance costs (USD Mn) | 0 | 0 | 0 | 545 | 0 |
Net FX loss (USD Mn) | 0 | 0 | 0 | 221 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansValuation Snapshot
| Metric | Value |
|---|---|
Revenue CAGR FY2021–FY2025 (%) | 1.0 (4,900 → ~5,100; approximate) |
Revenue CAGR FY2022–FY2025 (%) | -4.2 (post-inflation-peak normalisation) |
FY2020 revenue | ~$4.2bn (SpecChem); FY2020 adjusted EBITDA $984M (FY2021 release) / ~$970M (SpecChem) — sources differ slightly |
Cash Flow and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net cash from operating activities (USD Mn) | 0 | 677 | 996 | 968 | 0 |
Capital expenditure (USD Mn) | 0 | 0 | 392 | 240 | 0 |
Free cash flow (USD Mn) | 0 | 0 | 604 | 728 | 0 |
FCF / adjusted EBITDA (%) | 0 | 0 | 57 | 63 | 0 |
Dividends paid (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Income Statement
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net debt leverage (x LTM adj. EBITDA) | 0 | 0 | 5.7 | 5.0 | 0 |
Net total debt (USD Mn) | 0 | 0 | 6,014 | 5,775 | 0 |
Term loans refinanced in 2026 (USD Mn equiv.) | 0 | 0 | 0 | 0 | 5,776 |
Financial Ratios (x) and Income Statement
| Ratio | FY2023 | FY2024 | Comment |
|---|---|---|---|
Net debt / adjusted EBITDA (x) | 5.7 | 5.0 | Reported |
Adjusted EBITDA / finance costs (x) | — | 2.1 | Derived: 1,155 / 545 |
Revenue / employee (USD K) | 630 | 628 | Derived from headcount |
Adjusted EBITDA / employee (USD K) | 128 | 141 | Derived |
Region revenue (USD Mn)
| Region revenue (USD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Americas | 0 | 0 | 0 |
EMEA | 0 | 0 | 0 |
Asia-Pacific | 0 | 0 | 0 |
Region Overview
| Region | Headcount | % of total |
|---|---|---|
Europe | 3,578 | 44 |
Asia-Pacific | 1,945 | 24 |
North America | 1,553 | 19 |
South America | 1,057 | 13 |
Total | 8,133 | 100 |
Capital Markets
| Item | Status |
|---|---|
Share price performance (1/3/5-yr) | Not applicable — no listed equity |
P/E, EV/EBITDA, EV/Sales, P/B | Not applicable. Implied entry multiple: €10.1bn EV (2018). Reported IPO valuation talk ~€13bn (2024) ≈ ~12x FY2024 adjusted EBITDA (derived, approximate, currency-mixed) |
Analyst consensus | Not applicable (no equity coverage) |
Dividends / buybacks | None publicly disclosed |
Credit Ratings
| Agency | Instrument rating (2026 secured notes) | Outlook |
|---|---|---|
Moody's | B2 | Stable |
S&P | B+ | Stable |
Fitch | BB- | Stable |
Capital Instruments
| Instrument | Amount | Pricing | Maturity |
|---|---|---|---|
USD Term Loan B (new) | US$3,350M | Floating (SOFR + margin, n/d) | ~2031 (n/d exact) |
EUR Term Loan B (new) | €1,692M | Floating (EURIBOR + margin, n/d) | ~2031 (n/d exact) |
Senior Secured Notes | €450M | 6.125% fixed | 15 Jul 2031 (callable from 15 Jul 2027 at 102) |
Revolving credit facility | n/d (upsized/extended 2024–25) | — | — |
Receivables securitization | n/d (upsized/extended 2024–25) | — | — |
Debt maturity (USD Mn equiv., approximate)
| Debt maturity (USD Mn equiv., approximate) | FY2026 | FY2027 | FY2028 | FY2029 | FY2030 | FY2031 |
|---|---|---|---|---|---|---|
Scheduled maturities | 0 | 0 | 0 | 0 | 0 | 5,830 |
Analyst Conclusions
Management guidance
None published. Qualitative tone: in the FY2024 release management said it entered 2025 with stable market conditions and positive momentum from capex investments. FY2025 revenue of ~$5.1bn implies a flat year.
Bull case
-
Mix upgrade toward structural growth niches — GLP-1 purification (Kromasil® ×2), solar polyolefin catalysts (MMAO), bio-based detergent ingredients and South American pulp give Nouryon above-GDP volume levers with high margins.
-
Operating leverage and margin durability — FY2024 showed 220bp margin expansion on flat revenue; normalising volumes on a lower cost base could push margins toward the mid-20s.
-
Deleveraging plus exit catalyst — sustained ~$700M+ FCF and an extended maturity wall support leverage moving toward 4x, which would improve IPO feasibility at a valuation above the €10.1bn entry.
Bear case
-
Capital structure drag — ~$545M annual finance costs consume roughly half of adjusted EBITDA; rate or FX shocks drive IFRS losses (−$339M in FY2024).
-
Top-line stagnation — revenue has been flat-to-down for three years (5.19 → 5.13 → ~5.1bn), raising questions about organic growth claims.
-
Exit risk — multiple deferred IPOs suggest public-market investors may not pay the valuation sponsors seek; a sponsor-to-sponsor sale or dividend recap would maintain high leverage.
Catalysts and monitorables (next 12 months)
| Catalyst | Why it matters |
|---|---|
| FY2025 / FY2026 results disclosure | Confirms EBITDA trend and leverage after 2025 |
| IPO re-filing or launch | Primary sponsor exit route |
| Nobian sale outcome | Sponsor portfolio signal; supply relationship |
| China capacity utilisation (peroxides, alkyls, silica) | Return on 2023–2026 China capex |
| Kromasil® Sweden capacity start-up | GLP-1 growth exposure |
| Process safety trend | 2025 regression must reverse |
| Credit rating actions | Leverage path |
| Bolt-on M&A | Strategy execution |
Concluding analyst verdict
Nouryon is a well-run, high-margin specialty chemicals carve-out held back by a leveraged-buyout capital structure and by the absence of a completed exit eight years after the AkzoNobel separation. Operationally the evidence is constructive: the business absorbed the 2023 destocking with a 16% EBITDA decline, then recovered to $1.155bn of adjusted EBITDA and a 22.5% margin in 2024 on 6.5% volume growth, while converting more than 60% of EBITDA into free cash flow. Its niche franchises — metal alkyls, Expancel®, Kromasil®, chelates, Levasil® and South American pulp chemistry — are technically defensible and increasingly tied to durable themes such as peptide therapeutics, lightweighting, circular plastics and bio-based reformulation. Management, largely recruited from Carlyle's Axalta playbook, has executed a coherent programme of bolt-on acquisitions, emerging-market localisation and disciplined capex.
The constraint is financial rather than operational. At roughly 5x net leverage, finance costs consume around half of adjusted EBITDA, FX swings produce reported losses, and the company's growth capex and M&A capacity remain bounded. The mid-2026 refinancing removed the 2028 maturity wall and confirmed lender confidence (B2/B+/BB- stable), but it also signals that a near-term IPO was not the sponsors' preferred path. Top-line stagnation since 2022 — partly price normalisation — makes the equity story dependent on margin and mix rather than growth, which public investors typically value less generously.
For credit investors, Nouryon screens as a solid single-B credit with improving fundamentals, strong cash conversion and diversified end-markets. For prospective equity investors, the investment case hinges on demonstrating mid-single-digit organic growth and deleveraging toward 4x before an IPO. Absent FY2025 financial disclosure, conviction should remain moderate: positive on business quality, neutral on capital structure, and watchful on the exit timeline.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Joined / tenure | Prior roles | Education |
|---|---|---|---|---|
Charlie Shaver | Chairman & CEO | 2018 | Chairman & CEO, Axalta Coating Systems (2013–2018); CEO, TPC Group (2004–2011); Dow Chemical (1980–1996); Chairman of Nobian | B.S. Chemical Engineering, Texas A&M |
Sean Lannon | EVP & CFO | Mar 2024 | CFO, Copeland; SVP & CFO, Axalta (5 yrs); Styron/Trinseo, Endo, PwC | B.S. Accounting, Philadelphia University; CPA |
Michael Finn | EVP Business Affairs, General Counsel & Corporate Secretary | 2018 | GC, Axalta (6 yrs); General Dynamics (11 yrs); Willkie Farr; FCC | B.S. Finance, Indiana Univ.; J.D., NYU |
Jennifer Durbin | EVP & CHRO | 2026 | SVP, Chief HR & Communications Officer, CMC; Sidley Austin | B.S. Biomedical Eng., Univ. of Iowa; J.D., Boston Univ. |
Paresh Bhakta | EVP, Chief Integrated Supply Chain Officer | 2020 | SVP Operations, Henkel; DSM; Celanese | B.S. Chemical Eng., UT Austin |
Sandeep Singh | SVP, Chief Digital & Information Officer | — | Global CIO, Hunter Douglas; Campbell Soup; EY; PwC; P&G | B.S. Agricultural Eng. (CAET Ludhiana); MBA, Bowling Green |
Joe Lupia, Ph.D. | SVP & CTO | Jul 2026 | SVP Technology & Product Stewardship / CTO, Elementis; BASF | Ph.D. Organic Chemistry, Seton Hall; B.S. Biochemistry, Univ. of Scranton |
Egbert Henstra | SVP Global Transformation & President Netherlands | Akzo heritage | MD Global Ethylene & Sulfur Derivatives (Shanghai); VNCI board | Business Economics, Erasmus Univ. |
Eduardo Nardinelli | SVP South America & Global Carbon Business Strategy | 2021 | President Global Light Vehicle Coatings, Axalta; Johnson Controls; SKF | Mech. Eng., FAAP; MBA, Univ. of São Paulo |
Suzanne M. Carroll | EVP, Consumer & Life Sciences | 2019 | DuPont; Dow (9 yrs); Rohm and Haas (19 yrs); Chair, American Cleaning Institute | B.S. Chemistry, Saint Joseph's Univ. |
Alain Rynwalt | SVP, Performance Materials | 30+ yrs (heritage) | SVP Polymer Specialties | Master's Economics, Ghent |
Joppe Smit | SVP, Resource Solutions | 25+ yrs (heritage) | SVP Natural Resources, Intermediates, Paints & Coatings | M.Sc. Chem. Eng., Delft (cum laude) |
Sobers Sethi | SVP, Emerging Markets & China | 2020 | Axalta (carve-out team) | Economics, Clark Univ.; MBA, Cass |
Vivi Hollertt | VP, Chief Sustainability Officer | 2014 (heritage) | FleishmanHillard; Heineken spokesperson | M.A. Int'l Communication Mgmt |
Amy Chiconas | VP, Chief Communications Officer | 2025 | Vibrantz (2022–25); Ingevity (2016–22) | MBA, Univ. of South Carolina |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
Jun 2023 | CFO Renier Vree died | Vree had been CFO since the 2018 carve-out |
Mar 2024 | Sean Lannon appointed EVP & CFO | Former Axalta CFO; IPO-readiness signal |
Q3 2024 | Segment reorganisation; Larry Ryan (then President) quoted on new structure | Larry Ryan does not appear on the 2026 leadership page — departure date/context n/d |
| 2025 | Amy Chiconas appointed CCO | Communications function separated from sustainability |
| 2026 | Jennifer Durbin appointed CHRO | Replaces earlier HR leadership (Elsbeth Janmaat was appointed CHRO in an earlier period; exact succession n/d) |
Jul 2026 | Joe Lupia appointed CTO | Succeeds Philip Clark (appointed CTO Dec 2022); succession timing n/d |
Board of Directors
| Director | Role / committees | Affiliation |
|---|---|---|
Charlie Shaver | Chairman | Nouryon CEO |
Julie Aslaksen | Chair, Nominating & Corporate Governance; Compensation | EVP & GC, Host Hotels & Resorts |
Brian A. Bernasek | Director | Partner, Co-Head Americas Corporate PE, Carlyle |
Gregor P. Boehm | Chair, Executive Committee; Compensation | Chairman Europe PE, Carlyle |
Volkert Doeksen | Director | Former MD, Carlyle; co-founder AlpInvest |
Curtis Espeland | Chair, Audit | Former CFO, Eastman Chemical; director Lincoln Electric, Huntsman |
Tanaka J.J. Maswoswe | Audit | MD, Carlyle |
Gregory M. Nikodem | Audit | MD, Carlyle |
Melanie Steiner | Chair, Corporate Responsibility | CEO, Inspirion Group; former Chief Risk Officer, PVH |
Martin W. Sumner | Executive; Chair, Compensation; Nominating & Governance | MD, Head of Global Industrial & Transportation, Carlyle |
Noelle Walsh | Audit; Corporate Responsibility | President, Cloud Operations & Innovation, Microsoft |
Michael Zacka | Corporate Responsibility; Audit | Interim CEO, Klöckner Pentaplast; ex-Amcor CCO |
Governance Detail
| Board metric (31 Dec) | 2023 | 2024 | 2025 |
|---|---|---|---|
Directors (number) | 12 | 12 | 12 |
Independent directors (number, as reported) | 11 | 11 | 11 |
Women on board (number) | 3 | 3 | 3 |
Average tenure (years) | 4 | 4 | 5 |
Major Shareholders
| Holder | Stake | Comment |
|---|---|---|
The Carlyle Group (funds incl. Carlyle Partners / Carlyle Europe Partners) | n/d (majority, lead sponsor) | Acquired 2018 with GIC |
GIC Private Limited (Singapore) | n/d (minority co-investor) | Co-acquirer 2018 |
Institutional / public float | 0 | No listed equity |
Competitive Landscape
Competitors by Segment
| Nouryon business | Principal competitors |
|---|---|
Surfactants & HPC ingredients | BASF, Dow, Clariant, Croda, Evonik, Stepan, Solvay/Syensqo |
Chelates (cleaning, ag micronutrients) | BASF (incl. GLDA launch 2025), Dow, ICL, Valagro/Syngenta biologicals (adjacent), Aries Agro (India) |
Cellulose ethers / CMC | Ashland, Dow, CP Kelco, Shin-Etsu, Lotte Fine Chemical |
Organic peroxides | Arkema, United Initiators, Pergan |
Metal alkyls | Lanxess (ex-Chemtura), Albemarle (historical), Nippon Aluminum Alkyls, Tosoh |
Expandable microspheres | Matsumoto Yushi-Seiyaku, Sekisui, Kureha |
Chromatography silica | YMC, Osaka Soda (Daiso), Fuji Silysia, Merck KGaA |
Colloidal silica | Nissan Chemical, W.R. Grace, Evonik, Fuso |
Pulp bleaching chemicals | Kemira, ERCO Worldwide, Solenis, Chemtrade |
Oilfield & mining chemicals | ChampionX/SLB, Clariant Oil Services, Solenis, Ecolab/Nalco |
Peer Comparison FY2031
| Metric | Nouryon | Evonik | Clariant | Ashland |
|---|---|---|---|---|
Revenue (local currency M) | 5,130 | 15,200 | 4,150 | 2,110 |
Currency | USD | EUR | CHF | USD |
Adjusted EBITDA margin (%) | 22.5 | 13.6 | 17.0 | 23.0 |
Revenue growth YoY (%) | -1.1 | 0.9 | -5.0 | -3.0 |
R&D % of revenue | 0 | 3.0 | 2.5 | 2.5 |
Recent Developments
Not found in public sources reviewed: * FY2025 results release, quarterly 2025/2026 results, layoffs, litigation updates, or formal IPO launch.
